Objects
Choung, R. S., Locke III, G. R., Talley, N. J., Francis, D. D., Katzka, D., Winkle, P. J., Orr, W. C., Crowell, M. D., Devault, K., Harmsen, W. S., Zinsmeister, A. R.. Wiley-Blackwell; 2014. Novel partial 5HT3 agonist pumosetrag reduces acid reflux events in uninvestigated GERD patients after a standard refluxogenic meal: a randomized, double-blind, placebo-controlled pharmacodynamic study.
Koloski, N. A., Jones, M., Talley, N. J., Holtmann, G., Hammer, J., von Wulffen, M., Shah, A., Hoelz, H., Kutyla, M., Burger, D., Martin, N., Gurusamy, S. R.. Springer; 2017. The validity of a new structured assessment of gastrointestinal symptoms scale (SAGIS) for evaluating symptoms in the clinical setting.
Kruis, W., Kardalinos, V., Tuculanu, D., Tulassay, Z., Banai, J., Curtin, A., Dorofeyev, A. E., Zakko, S. F., Ferreira, N., Björck, S., Diez Alonso, M. M., Mäkelä, J., Eisenbach, T., Talley, N. J., Lukas, M., Pokrotnieks, J., Derova, J., Kondrackiene, J., Safadi, R.. Wiley-Blackwell; 2017. Randomised clinical trial: mesalazine versus placebo in the prevention of diverticulitis recurrence.
Marks, E., Naudin, C., Callister, R., Veysey, M., Walker, M. M., Talley, N. J., Radford-Smith, G., Keely, S., Nolan, G., Goggins, B. J., Burns, G., Mateer, S. W., Latimore, J. K., Minahan, K., Plank, M., Foster, P. S.. Nature Publishing Group; 2017. Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation.
Windsor, J., Searle, J., Smith, J. A., Wainer, Z., Talley, N. J., Gladman, M. A., Hanney, R., Chapman, A., Grigg, M., Choong, P., Mackay, A., Smithers, B. M., Churchill, J. A., Carney, S.. Wiley-Blackwell; 2015. Building a sustainable clinical academic workforce to meet the future healthcare needs of Australia and New Zealand: report from the first summit meeting.
Pilichiewicz, A. N., Andrews, J. M., Goess, C., McMahon, J., Fraser, R. J., Beilby, J., Holloway, R. H., Talley, N. J., Holtmann, G.. Wiley-Blackwell Publishing; 2011. A preliminary analysis of the effect Iberogast, Nexium, dual Iberogast + Nexium or dual placebo on symptoms in patients with functional dyspepsia.